Dare Bioscience, Inc.
Summary
Dare Bioscience, Inc. filed a Form D on 2026-06-02, raising $65.0M in a private placement backed by Flagship Pioneering and ARCH Venture Partners. The first sale date was 2026-06-01, indicating the capital is already deployed. This is a significant raise for a private company in the Technology Venture sector.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Full Analysis
Executive Summary
Dare Bioscience, Inc. filed a Form D on 2026-06-02, raising $65.0M in a private placement backed by Flagship Pioneering and ARCH Venture Partners. The first sale date was 2026-06-01, indicating the capital is already deployed. This is a significant raise for a private company in the Technology Venture sector.
Investor Edge
Watch for a subsequent Form D/A amendment, which would indicate additional capital or changed terms, signaling strong demand or a pivot in strategy. Also monitor for any public announcements from Dare Bioscience regarding partnerships or regulatory milestones.
Sector capital positioning
This $65M raise signals strong institutional appetite for high-risk, high-reward technology ventures, particularly those with ties to top-tier life science venture firms.
Convergence Signals
No direct public signals are evident from the filing data. However, the involvement of Flagship Pioneering and ARCH Venture Partners suggests potential connections to novel platform technologies or therapeutic assets that may have patent filings or upcoming clinical milestones.
Key Takeaways
- Dare Bioscience raised $65.0M in a private placement with first sale on 2026-06-01.
- Backed by elite venture firms Flagship Pioneering and ARCH Venture Partners.
- No public ticker; this is a private company filing a Regulation D notice.
Risk Indicators & Flags
No red flags in this initial Form D filing. The amount is large but consistent with the backing of top-tier VCs. No D/A amendments yet. Sector is Technology Venture, which is broad; specific risk depends on the company's actual product or service, which is not disclosed in the filing.
Verification & References
Filing is a Form D (initial notice) with SEC accession 000149315226026666. Verified via SEC EDGAR at https://www.sec.gov/cgi-bin/browse-edgar?company=DEFA14A%20-%20Dare%20Bioscience%2C%20Inc.%20(0001401914)%20(Filer)&type=D&action=getcompany. Amount raised is $65.0M. Related persons include Flagship Pioneering and ARCH Venture Partners.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Anika Therapeutics, Inc.
Matthias Therapeutics, LLC
Uniform Bio Inc.
Outlook Therapeutics, Inc.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Streamlining Access to Government Services Through America.gov
The executive order directs the General Services Administration to create America.gov, a unified digital portal for federal services, integrating Login.gov for authentication and requiring agencies to expose their digital services via APIs. It also mandates the use of AI (referred to as 'super intelligence') with transparency safeguards, while preserving existing service channels and excluding tax and defense/intelligence services.
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Restriction on Entry of Certain Nonimmigrant Workers
This proclamation extends for an additional 12 months the existing restriction on entry of H-1B nonimmigrant workers, which requires a $100,000 payment per petition (with limited exceptions) and is supported by a DHS weighted selection process that prioritizes higher-skilled, higher-paid workers. The action continues to target IT staffing and outsourcing firms that have abused the program, and it maintains the requirement for ongoing rulemakings by DHS and DOL to further reform wage protections and program integrity.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →